ExpreS2ion Biotech Holding AB
ExpreS2ion Biotech Holding AB (publ), a biotechnology company, develops vaccines and biologics products to address critical unmet medical needs in the Nordics and internationally. The company's lead asset is ES2B-C001, a therapeutic vaccine which is in Phase 1 clinical trials for breast cancer that targets the human epidermal growth factor receptor 2. It is also developing ES2B-I002, a cytomegalo… Read more
ExpreS2ion Biotech Holding AB - Asset Resilience Ratio
ExpreS2ion Biotech Holding AB (EXPRS2) has an Asset Resilience Ratio of 5.64% as of December 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2018–2023)
This chart shows how ExpreS2ion Biotech Holding AB's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down ExpreS2ion Biotech Holding AB's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr0.00 | 0% |
| Short-term Investments | Skr4.44 Million | 5.64% |
| Total Liquid Assets | Skr4.44 Million | 5.64% |
Asset Resilience Insights
- Limited Liquidity: ExpreS2ion Biotech Holding AB maintains only 5.64% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
ExpreS2ion Biotech Holding AB Industry Peers by Asset Resilience Ratio
Compare ExpreS2ion Biotech Holding AB's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
MedPacto Inc
KQ:235980 |
Biotechnology | 49.82% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for ExpreS2ion Biotech Holding AB (2018–2023)
The table below shows the annual Asset Resilience Ratio data for ExpreS2ion Biotech Holding AB.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 5.64% | Skr4.44 Million | Skr78.69 Million | +6.75pp |
| 2022-12-31 | -1.12% | Skr-1.53 Million | Skr137.36 Million | -68.09pp |
| 2021-12-31 | 66.97% | Skr101.77 Million | Skr151.96 Million | +67.79pp |
| 2020-12-31 | -0.81% | Skr-966.00K | Skr118.86 Million | +4.17pp |
| 2019-12-31 | -4.99% | Skr-933.00K | Skr18.71 Million | -1.73pp |
| 2018-12-31 | -3.25% | Skr-682.00K | Skr20.95 Million | -- |